Inhibikase Therapeutics (IKT) Enterprise Value (2020 - 2026)
Inhibikase Therapeutics (IKT) has 7 years of Enterprise Value data on record, last reported at -$170.4 million in Q1 2026.
- On a quarterly basis, Enterprise Value fell 82.84% to -$170.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$170.4 million, a 82.84% decrease, with the full-year FY2025 number at -$178.8 million, down 83.27% from a year prior.
- Enterprise Value reached -$170.4 million in Q1 2026 per IKT's latest filing, up from -$178.8 million in the prior quarter.
- Over the last five years, Enterprise Value for IKT hit a ceiling of -$3.2 million in Q3 2024 and a floor of -$178.8 million in Q4 2025.
- A 5-year average of -$54.2 million and a median of -$26.5 million in 2022 define the central range for Enterprise Value.
- Peak YoY movement for Enterprise Value: surged 80.73% in 2024, then crashed 2283.81% in 2025.
- Tracing IKT's Enterprise Value over 5 years: stood at -$23.1 million in 2022, then surged by 42.51% to -$13.3 million in 2023, then tumbled by 636.06% to -$97.5 million in 2024, then plummeted by 83.27% to -$178.8 million in 2025, then rose by 4.7% to -$170.4 million in 2026.
- Business Quant data shows Enterprise Value for IKT at -$170.4 million in Q1 2026, -$178.8 million in Q4 2025, and -$77.3 million in Q3 2025.